News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Resolv ER may remedy leading causes of blindness in adults
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Vonage Communications APIs allow developers to easily enhance and build intelligent, intuitive customer experiences directly into their existing applications and devices
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Takes charge to lead business innovation, strategy, alliance & partnerships
The aim is to strengthen industry-academia cooperation
The new centre will comprise a team of 50 highly experienced specialists
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Subscribe To Our Newsletter & Stay Updated
